ReviewAlcohol research : current reviews2021
Alcohol Use Disorder: The Role of Medication in Recovery.
Review in Alcohol research : current reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review.Metabolic brain disease · 2025Pooled it
- Relief craving severity moderates nonpharmacological treatment outcomes in treatment-seeking older adults with alcohol use disorder.Alcohol, clinical & experimental research · 2025Trial
- Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorder.Journal of psychiatric research · 2024Trial
- Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.Scientific reports · 2024Trial
- Multi-omics and electrophysiological examination of GABAMolecular psychiatry · 2026Article
- Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements.The Milbank quarterly · 2026Article
- Ivermectin reduces withdrawal-induced alcohol intake in rats: Association with CeA GABAergic enhancement and P2rx4 genetic liability.Neuropharmacology · 2026Article
- Exploring the association between sweet liking and treatment response to naltrexone in patients with alcohol use disorder.The international journal of neuropsychopharmacology · 2026Article
- Development of a mid-infrared transflection probe and in-vitro feasibility for ethanol monitoring.Talanta · 2026Article
- Engagement of the Paraventricular Nucleus of the Thalamus During Withdrawal-Related Learning: Implications for Alcohol Use Disorder.Biological psychiatry global open science · 2026Article
- Alpha-2 Adrenergic Agonists Reduce Heavy Alcohol Drinking and Improve Cognitive Performance in Mice.eNeuro · 2026Article
- Convergence of sociodemographic, clinical, regulatory, and quality characteristics in pharmacotherapeutic management of alcohol use disorder: a scoping review protocol.Systematic reviews · 2025Article
- Ivermectin Reduces Withdrawal-Induced Alcohol Intake via CeA GABAergic Enhancement.bioRxiv : the preprint server for biology · 2025Article
- Chronic intermittent ethanol produces nociception through endocannabinoid-independent mechanisms in mice.Neuropharmacology · 2025Article
- Activation of anoctamin-1 calcium-activated chloride channels reduces voluntary alcohol consumption in rats.Neuropharmacology · 2025Article
- A single-cell genomic atlas for the effects of chronic ethanol exposure in the mouse dorsal striatum.Molecular psychiatry · 2025Article
- ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions.CNS drugs · 2025Review
- Exposure to disulfiram and incidence of parkinsonism.Journal of occupational medicine and toxicology (London, England) · 2025Article
- Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans.JAMA network open · 2025Article
- Chronic intermittent ethanol produces nociception through endocannabinoid-independent mechanisms in mice.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The misuse of alcohol in the United States continues to take a large toll on society, resulting in the deaths of about 88,000 Americans per year. Moreover, it is estimated that nearly 14.6 million Americans currently meet diagnostic criteria for current alcohol use disorder (AUD). However, very few individuals receive treatment, with an even smaller portion receiving medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of AUD, despite scientifically rigorous evidence showing the benefits of combining medication approved for treating AUD with evidence-based behavioral therapy. These benefits include higher rates of abstinence and less risk of relapse to heavy drinking, with associated improvements in medical and mental health and in quality of life. This review provides an overview of FDA-approved medications and "off-label" drugs for the treatment of AUD. The article emphasizes that AUD medical advice and prescription recommendations should come from professionals with training in the treatment of AUD and that treatment plans should consider medication in conjunction with evidence-based behavioral therapy. Finally, this review notes the limited number of medications available and the continued need for the development of new pharmacotherapies to optimize AUD recovery goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.